1. Public Health Considerations for the Introduction of New Rotavirus Vaccines for Infants: A Case Study of Tetravalent Rhesus Rotavirus-based Reassortant Vaccine
- Author
-
John D. Clemens, Abdollah Naficy, Roger I. Glass, Neysa Keckich, and Malla Rao
- Subjects
Rotavirus ,medicine.medical_specialty ,Pediatrics ,Epidemiology ,viruses ,Population ,Vaccines, Attenuated ,medicine.disease_cause ,Rotavirus Infections ,medicine ,Animals ,Humans ,Intensive care medicine ,education ,Disease burden ,education.field_of_study ,business.industry ,Public health ,Vaccination ,Rotavirus Vaccines ,Infant ,virus diseases ,Viral Vaccines ,General Medicine ,Macaca mulatta ,United States ,Clinical trial ,Diarrhea ,Immunization ,medicine.symptom ,business - Abstract
This paper discusses considerations in public health for the introduction of tetravalent rhesus rotavirus-based reassortant vaccine (RRV-TV) for infants. RRV-TV contains a mixture of G1, G2, and G4 reassortants with a parent strain of MMU 18006. Field trials were performed to evaluate the protective efficacy of RRV-TV in infants and to determine the efficacy of RRV-TV higher-dose regimen. The use of RRV-TV in infant immunization brings about the following relevant issues: 1) availability of alternative or complementary non-vaccine interventions; 2) burden of disease; 3) epidemiologic features of rotavirus disease; 4) protective characteristics of the vaccine in efficacy trials; 5) clinical effectiveness of the vaccine; and 6) balance between costs and benefits of vaccination. Moreover, due to its high cost, RRV-TV would not be a cost-saving public health tool in developing countries unless it is made affordable. An effective vaccine against rotavirus is needed due to the following factors: 1) immense burden of rotavirus; 2) persistence of disease burden despite the promotion of rehydration therapy for acute diarrheas in childhood; and 3) lack of effectiveness of nonvaccination approaches.
- Published
- 1999
- Full Text
- View/download PDF